 BALA CYNWYD, Pa., May 20, 2021 GLOBE NEWSWIRE -- Larimar Therapeutics, Inc. Larimar Nasdaq: LRMR, a clinical-stage biotechnology company focused on developing treatments for Friedreichs ataxia FA and other complex rare diseases, today announced that the European Medicines Agency EMA has granted Priority Medicines PRIME designation to CTI-1601 for the treatment of FA. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with FA who are unable to produce enough of this essential protein. 